SCHEMBL2441233

SCHEMBL2441233

Cc1ccc2onc(NC(=O)c3cccc(F)c3)c2c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.74
TP53 P04637 5/20 0.74
CYP1A2 P05177 1/20 0.57
CYP2C19 P33261 1/20 0.57
KCNK3 O14649 1/20 0.53
KCNK9 Q9NPC2 1/20 0.53
KCNQ3 O43525 1/20 0.49
KCNQ2 O43526 1/20 0.49
KCNQ5 Q9NR82 1/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
TSHR P16473 2/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
ALOX15 P16050 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
USP2 O75604 1/20 0.46
MAPT P10636 5/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2440241 0.90 SMN1; SMN2 (0.58) SMN1; SMN2TP53KCNK3KCNK9MEN1
SCHEMBL2440202 0.86 SMN1; SMN2 (0.68) SMN1; SMN2TP53MEN1KMT2ANPC1
SCHEMBL2437851 0.86 TP53 (0.56) SMN1; SMN2TP53KCNK3KCNK9MEN1
SCHEMBL2440970 0.81 MAPT (0.51) SMN1; SMN2TP53CYP1A2CYP2C19ALDH1A1
SCHEMBL2439676 0.80 TP53 (0.54) SMN1; SMN2TP53MEN1KMT2AALDH1A1
SCHEMBL2439567 0.80 SMN1; SMN2 (0.56) SMN1; SMN2TP53MEN1KMT2AALDH1A1
SCHEMBL2437978 0.79 SMN1; SMN2 (0.51) SMN1; SMN2TP53MEN1KMT2AGAA
SCHEMBL2440155 0.78 SMN1; SMN2 (0.52) SMN1; SMN2TP53CYP1A2CYP2C19KCNK3
SCHEMBL2438973 0.77 TP53 (0.64) SMN1; SMN2TP53CYP1A2CYP2C19KCNK3
SCHEMBL2438553 0.77 RAB9A (0.54) SMN1; SMN2TP53KCNK3KCNK9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP claimed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US claimed
EP-1893589-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-03-05 EP claimed
WO-2006131296-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-14 WO claimed
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP disclosed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
EP-1893589-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-03-05 EP disclosed
WO-2006131296-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof HTR5A, NPY5R, GRM5 SMN1; SMN2 2423/4885TP53 4882/4885CYP1A2 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.